Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

被引：10

作者：

Agarwal, Neeraj

Shore, Neal D.

Dunshee, Curtis

Karsh, Lawrence Ivan

Sullivan, Beth

Di Santo, Nicola

Elmeliegy, Mohamed

Lin, Xun

Czibere, Akos Gabor

Fizazi, Karim

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[3] Urol Associates Southern Arizona, Tucson, AZ USA

[4] Urol Ctr Colorado, Denver, CO USA

[5] Pfizer Inc, Groton, CT 06340 USA

[6] Pfizer Inc, Durham, NC USA

[7] Pfizer Inc, La Jolla, CA USA

[8] Pfizer Inc, Cambridge, MA USA

[9] Gustave Roussy Canc Ctr, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.5076

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5076

引用

页数：1